University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients - Seite 2

the recent BMC Cancer paper,5 "Prospective study evaluating dynamic changes of
cell-free HPV-DNA in locoregional viral-associated oropharyngeal cancer treated
with induction chemotherapy and response-adaptive treatment."

The trial is a follow-on to the poster6 presented at the 2021 ASCO Annual
Meeting in which Dr. Agrawal described how HPV-SEQ exhibits robust quantitative
detection of cfHPV-DNA across a broad dynamic range, thus enabling
high-resolution monitoring for patients with HPV positive OPC.

HPV-SEQ is available as a testing service provided by the Sysmex Inostics CLIA
lab in Baltimore. MD.

1. https://clinicaltrials.gov/ct2/show/record/NCT04572100

2. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/
chemotherapy/chemotherapy-side-effects.html

3. https://ascopubs.org/doi/10.1200/EDBK_325319?url_ver=Z39.88-2003&rfr_id=ori:r
id:crossref.org&rfr_dat=cr_pub%20%200pubmed

4. https://www.hopkinsmedicine.org/kimmel_cancer_center/cancers_we_treat/head_ne
ck/hpv/faqs.html

5. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-09146-z

6. https://sysmex-inostics.com/new-asco-2021-poster-highlights-hpv-seq-tests-ult
ra-sensitive-detection-of-hpv-16-18-in-plasma/

About Sysmex Inostics

Sysmex Inostics, Inc., a US-based Sysmex Corporation subsidiary, empowers
discoveries in oncology by providing investigators with ultra-sensitive,
quantitative, and cost-effective CLIA-validated liquid biopsy services.

Since 2008, Sysmex Inostics has provided leading Pharma companies custom liquid
biopsy assay services, first OncoBEAM(TM) and now Plasma-Safe-SeqS, to support
real-time therapy selection and targeted-mutational monitoring during and after
treatment throughout the clinical trial process.

Developed by experts at Johns Hopkins with the philosophy of "no molecule left
behind," Sysmex Inostics Plasma-Safe-SeqS has robust detection as low as 0.03%
allele frequency (for input of 20,000 genomic equivalents) without sacrificing
specificity. The venerable OncoBEAM(TM) digital PCR cell-free DNA (cfDNA)
technology has been employed in hundreds of pivotal studies, publications, and
numerous drug discoveries in oncology. Plasma-Safe-SeqS NGS technology,
introduced in 2019, is currently being used in various clinical studies.

In July 2021, Sysmex Corporation announced a global strategic alliance with
QIAGEN to expedite clinical trial timelines and CDx development by uniting
QIAGEN's commercial and regulatory expertise with the liquid biopsy scientific
rigor and knowledge of Sysmex Inostics.

Sysmex Inostics offersPlasma-Safe-SeqS services in its CLIA-certified laboratory
in Baltimore, Maryland.

For more information, refer to http://www.sysmex-inostics.com or email
mailto:[e-mail] .

Contact:

Tracy Vandenbroek
Director, Marketing
Sysmex Inostics
+1.512.791.2899
mailto:[e-mail]

Additional content: http://presseportal.de/pm/114536/5131290
OTS: Sysmex Inostics GmbH